| Field | Specification |
|---|---|
| Target | |
| Alternative names | NF-kappa-B inhibitor beta;NF-kappa-BIB;I-kappa-B-beta;IkB-B;IkB-beta;IkappaBbeta;Thyroid receptor-interacting protein 9;TR-interacting protein 9;TRIP-9;NFKBIB;IKBB, TRIP9; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human IKB beta recombinant protein (Position: E56-E237). Human IKB beta shares 82% and 80% amino acid (aa) sequence identity with mouse and rat IKB beta, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets NF-kappa-B inhibitor beta (gene NFKBIB) in human, mouse and rat samples and is validated for IHC and Western blot. The predicted molecular weight is 37.8 kDa, and the supplier reports an observed band at about 45–48 kDa.
IκBβ (NFKBIB) is an inhibitor of NF-κB that traps NF-κB dimers in the cytoplasm. Compared with IκBα it is degraded more slowly after stimulation, and a newly made, unphosphorylated form can accompany NF-κB into the nucleus, which helps shape prolonged NF-κB responses.
| Target | NF-kappa-B inhibitor beta (gene NFKBIB; UniProt Q15653, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 37.8 kDa |
| Observed MW | 45–48 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells, human Jurkat cells, rat testis tissue, mouse testis tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Recombinant human IKB beta fragment (Glu56–Glu237), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 82% and 80%, respectively.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places NF-kappa-B inhibitor beta in the cytoplasm and nucleus. Tissue expression noted by UniProt (human): Expressed in all tissues examined. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Yuancan Pan et al. (2024) Scutellaria barbata D.Don and Scleromitrion diffusum (Willd.) R.J.Wang inhibits the progression of triple negative breast cancer though the activation inhibition of NF-κB triggered by CAFs-derived IL6. Journal of Ethnopharmacology. 10.1016/j.jep.2024.118656
